首页> Frontiers in pediatrics> Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.

Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.

导出 LinkOut

翻译打印收藏纠错

第一作者： Deepak,Chellapandian

第一单位： Center for Cell and Gene Therapy for Nonmalignant Conditions, Blood and Marrow Transplant Program, Johns Hopkins All Children's Hospital, St Petersburg, FL, United States.

作者： Deepak,Chellapandian ^[1] ; Diana,Milojevic ^[2]

作者单位： Center for Cell and Gene Therapy for Nonmalignant Conditions, Blood and Marrow Transplant Program, Johns Hopkins All Children's Hospital, St Petersburg, FL, United States. ^[1] Division of Pediatric Rheumatology, Johns Hopkins All Children's Hospital, St Petersburg, FL, United States. ^[2]

关键词 allogeneic hematopoietic stem cell transplantation case report emapalumab macrophage activation syndrome (MAS)systemic juvenile idiopathic arthritis (sJIA)

DOI 10.3389/fped.2023.1123104

PMID 36891226

发布时间 2023-03-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Frontiers in pediatrics

2023年11卷

1123104页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览1

点击下载本期目录封面

Frontiers in pediatrics

2023年11卷

1123104页

检索历史清除

Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.

Frontiers in pediatrics

相似文献

Frontiers in pediatrics

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.

Frontiers in pediatrics

相似文献

Frontiers in pediatrics

相关期刊

检索历史清除